9006 Background: MET exon 14 alterations comprise a novel class of lung cancer drivers.
MET tyrosine kinase inhibitors (TKIs) are active in patients with these cancers, but objective …

9069 Background: Non-small cell lung cancers (NSCLC) harboring METex14 activating
mutations can respond dramatically to treatment with MET TKIs, but the mechanisms of …

Opinion statement The MET exon 14 skipping mutation is found in approximately 3% of lung
adenocarcinomas and slightly more than 2% of lung squamous cell carcinomas. In recent …

MET signaling pathway has received increasing attention as a new therapeutic target in lung
cancer [1]. The MET pathway is also important for acquired resistance to EGFR-tyrosine …

Discussion The utilization of sensitive and comprehensive genomic profiling is critical to
provide unbiased molecular analysis of samples acquired in the setting of progression …

Introduction Alterations in the MET gene, including amplifications and exon 14 skipping
mutations, have been identified as actionable oncogenic alterations. However, MET fusions …

Background The c‐MET protein, encoded by the mesenchymal‐epithelial transition factor
(MET) gene, can regulate cell proliferation, migration and invasion. Studies have shown that …

PURPOSE MET exon 14 (MET ex14) skipping alterations are oncogenic drivers in non–
small-cell lung cancer (NSCLC). We present a comprehensive overview of MET ex14 …

A number of small molecule tyrosine kinase inhibitors (TKIs) have now been approved for
the treatment of non-small cell lung cancers (NSCLC), including those targeted against …

In the article by Yang et al.[1], it was identified that lung cancer patients with MET exon 14
(METex14) alterations achieve longer progression-free survival on crizotinib than on …